Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. The Diabetes Atorvastatin Lipid Intervention (DALI) Study: A randomized, double-blind, placebo-controlled trial

Diabetes Care

Volumn 25, Issue 7, 2002, Pages 1211-1216

  Van Venrooij, Francine V ^a   Van De Ree, Marcel A ^b   Bots, Michiel L ^a   Stolk, Ronald P ^a   Huisman, Menno V ^b   Banga, J D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; GLYCERYL TRINITRATE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PLACEBO; PYRROLE DERIVATIVE;

ARTICLE; B SCAN; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; BLOOD; BLOOD FLOW VELOCITY; BLOOD PRESSURE; FEMALE; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SMOKING; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; PYRROLES; SMOKING; VASODILATION;

EID: 0036632337     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.7.1211     Document Type: Article

References (42)

1. Syvanne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl. 1):SI20-SI23, 1997
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
3. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98:2513-2519, 1998
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
5. Goodfellow J, Ramsey MW, Luddington LA, Jones CJ, Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 312:744-745, 1996
6. Tooke JE, Goh KL: Vascular function in type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheliopathy. Diabet Med 16:710-715, 1999
7. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809, 1993
8. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F: Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86:207-210, 2000
9. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906, 2000
10. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 346:467-471, 1995
11. Vogel RA, Corretti MC, Plotnick GD: Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 77:37-40, 1996
12. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95:76-82, 1997
13. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within 1 month. Circulation 95:1126-1131, 1997
14. Raal FJ, Pilcher GJ, Veller MG, Kotze MJ, Joffe BI: Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol 84:1344-1346, 1999
15. Smilde TJ, Van Den Berkmortel FW, Wollersheim H, Van Langen H, Kastelein JJ, Stalenhoef AF: The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 30:473-480, 2000
16. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 139:577-583, 2000
17. Bakker-Arkema RG, Nawrocki JW, Black D: Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 149:123-129, 2000
18. Black D, Bakker-Arkema RG, Nawrocki JW: An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 158:577-584, 1998
19. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587, 1998
20. Simons LA, Sullivan D, Simons J, Celermajer DS: Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 137:197-203, 1998
21. Bakker Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133, 1996
22. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 81:66B-69B, 1998
23. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind randomized placebo-controlled trial in patients with type 2 diabetes mellitus and diabetic dyslipidemia. Diabetes Care 24:1335-1341, 2001
24. Liang Q, Wendelhag I, Wikstrand J, Gustavsson T: A multiscale dynamic programming procedure for boundary detection in ultrasonic artery images. IEEE Trans Med Imaging 19:127-142, 2000
25. Wilmink HW, de Kleijn MJ, Bots ML, Bak AA, van der Schouw YT, Engelen S, Planellas J, Banga J, Grobbee DE: Lipoprotein (a) is associated with endothelial function in healthy postmenopausal women. Atherosclerosis 153:249-254, 2000
26. Toikka JO, Ahotupa M, Viikari JSA, Niinikoski H, Taskinen MR, Irjala K, Hartiala JJ, Raitakari OT: Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 147:133-138, 1999
27. Li X, Zhao S, Zhang X, Liu L, Gao M, Zhou Q: Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 73:231-236, 2000
28. Dupuis J, Tardif J-C, Cernecek P, Théroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE trial. Circulation 99:3227-3233, 1999
29. Sheu WH, Juang BL, Chen YT, Lee WJ: Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 22:1224-1225, 1999
30. van de Ree MA, Huisman MV, De Man FH, van der Vijver JCM, Meinders AE, Blauw GJ: Impaired endothelium-dependent vasodilatation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 52:299-305, 2001
31. Watts GF, Playford DA: Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: a hypothesis. Atherosclerosis 141:17-30, 1998
32. Watts GF, O'Brien SF, Silvester W, Millar JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch) 91:567-573, 1996
33. Makimattila S, Liu M-L, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M, Schlenzka A, Lahdenpera S, Syvanne M, Mantysaari M, Summanen P, Bergholm R, Taskinen MR, Yki-Jarvinen H: Impaired endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care 22:973-981, 1999
34. Baron AD: Vascular reactivity. Am J Cardiol 84:25J-27J, 1999
35. Balletshofer BM, Rittig K, Enderle M, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784, 2000
36. Tribe RM, Poston L: Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc Med 1:195-206, 1996
37. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93:1331-1333, 1996
38. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20:545-550, 2000
39. Williams S, Abbott D, Morfis L, Manwaring P, Diamond T, Howes LG: Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. J Hypertens 16:705-711, 1998
40. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD: Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 31:322-328, 2001
41. Mancini GB: Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med 23: 144-161, 2000
42. Cannon RO III: Cardiovascular benefit of cholesterol-lowering therapy. Does improved endothelial vasodilator function matter? Circulation 102:820-822, 2000